Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Georganne Bradshaw"'
Autor:
Joseph E, Willis, Frederick, Eyerer, Eric E, Walk, Patricia, Vasalos, Georganne, Bradshaw, Sophia Louise, Yohe, Jordan S, Laser
Publikováno v:
Archives of Pathology & Laboratory Medicine. 147:62-70
Context.— Programmed death ligand-1 (PD-L1) immunohistochemistry companion diagnostic assays play a crucial role as predictive markers in patients being considered for immune checkpoint inhibitor therapy. However, because of a convergence of severa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ccd5d77211e729c2a0fe1228ddf061b
https://doi.org/10.5858/arpa.2021-0151-cp
https://doi.org/10.5858/arpa.2021-0151-cp
Autor:
Daniel F. Hayes, Roy S. Herbst, Jonathan L. Myles, Suzanne L. Topalian, Sophia L. Yohe, Naomi Aronson, Andrew M. Bellizzi, Upal Basu Roy, Georganne Bradshaw, Robin H. Edwards, Ehab A. El-Gabry, Julia Elvin, Thomas F. Gajewski, Lisa M. McShane, Matthew Oberley, Reena Philip, David L. Rimm, Jason N. Rosenbaum, Eric H. Rubin, Lisa Schlager, Shimere W. Sherwood, Mark Stewart, Janis M. Taube, Magdalena Thurin, Patricia Vasalos, Jordan Laser
Publikováno v:
JCO precision oncology. 6
PURPOSE Immune checkpoint inhibition (ICI) therapy represents one of the great advances in the field of oncology, highlighted by the Nobel Prize in 2018. Multiple predictive biomarkers for ICI benefit have been proposed. These include assessment of p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b0574760ad592209cc71ea721097435c
https://pubmed.ncbi.nlm.nih.gov/36446042
https://pubmed.ncbi.nlm.nih.gov/36446042
Autor:
Frederick Inglis Rudolf Eyerer, Georganne Bradshaw, Patricia Vasalos, Jordan Seth Laser, Chung-Che Chang, Annette Sunhi Kim, Damon R. Olson, Ronald Joseph Paler, Jason N. Rosenbaum, Eric E. Walk, Joseph E. Willis, Jinjuan Yao, Sophia Louise Yohe
Publikováno v:
Archives of pathologylaboratory medicine.
Context.— Neurotrophic receptor tyrosine kinase (NTRK) fusion testing has both diagnostic and therapeutic implications for patient care. With 2 tumor-agnostic US Food and Drug Administration–approved tropomyosin receptor kinase (TRK) inhibitors,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5d40d0885973c10ce8e5921132bb91aa
https://pubmed.ncbi.nlm.nih.gov/36508682
https://pubmed.ncbi.nlm.nih.gov/36508682